Research advances in nanomedicine in treatment of liver fibrosis

VernacularTitle:纳米药物治疗肝纤维化的研究进展
Author: Jialing GUO ^{1
,

2} ; Hui LI ¹ ; Zijian ZENG ^{1
,

2} ; Yujing TAO ^{1
,

2} ; Haijian DONG ^{1
,

2}
Author Information

1. Central Laboratory, The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
2. School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
Publication Type:Review
Keywords: Liver Cirrhosis; Nanoparticles; Drug Therapy
From: Journal of Clinical Hepatology 2023;39(2):413-418
CountryChina
Language:Chinese
Abstract: Liver fibrosis (LF) is a pathological process of hepatic stellate cell (HSC) activation and excessive deposition of extracellular matrix caused by chronic liver injury and inflammation. HSC activation is the core mechanism of LF, and inhibiting HSC activation is the key to promoting the reversal of LF. In recent years, rapid development has been achieved for the application of nanomedicine targeting HSC in the treatment of LF. This article mainly introduces nanomedicine, the mechanism of action of nanomedicine in the treatment of LF, and potential targets, and it is pointed out that nanomedicine may become a new method for the treatment of LF.